Home > Lynparza® (olaparib): PROpel NOC/c – Letter to physician users of the PSP for which it is determined
View in browser | FR






Dear Healthcare Provider,

As a user of the Lynparza Patient Support Program (PSP) for the PROfound indication in prostate cancer, AstraZeneca Canada and Merck Canada are writing to inform you about a recent change relating to the PSP.

On July 11th, 2023, Lynparza® (olaparib) was approved with conditions by Health Canada in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated. Lynparza has been issued conditional marketing authorization pending the results of studies to verify its clinical benefit. Patients should be advised of this conditional marketing authorization.

The PSP for Lynparza in BRCA mutated mCRPC offers:
  • Reimbursement navigation support

  • Co-payment towards the cost of the drug (up to 20 percent) for those with private insurance or who are paying out of pocket

  • A free drug program offering full coverage for Lynparza for eligible patients, as described below, who have enrolled in the PSP between the specific program dates

  • Access to educational resources

The free drug program for BRCA mutated 1L mCRPC will be open to eligible adult patients without private insurance on July 13th, 2023. To receive free drug, patients must be enrolled into the PSP and start on treatment before free drug program closure in September of 2024 or at public listing or until radiological disease progression, unacceptable toxicity, or patient/physician choice (whichever comes first). This is subject to change at any time. The eligibility criteria include:

  • Patient meets Health Canada approved indication: LYNPRAZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.

  • Patient must be BRCA 1 or BRCA 2 Positive by germline test and/or somatic test and corresponding test results must be provided

  • Patient has NOT received prior lines of therapy in the metastatic castrate-resistant setting

  • Patient has NOT received prior treatment with a Novel Hormone Agent (NHA)

  • Patient has NOT received prior treatment with a PARP-inhibitor

  • Patient has an ECOG performance status of zero (0) or one (1)

  • MD has confirmed that they understand that funding of abiraterone must be secured outside of the AZC Oncology PSP.


In the event that changes are made to the program, prescribing physicians will be notified in advance and any patients already enrolled in the program and on therapy will continue to receive uninterrupted access to Lynparza, for as long as they require treatment, and according to the eligibility criteria.

For questions about the PSP or to enroll a patient, please call 1-877-280-6208 (Monday through Friday, 8 a.m. to 8 p.m. ET) or email enrollment@azoncologypsp.ca. If you have any questions about Lynparza, please contact your local AstraZeneca or Merck representative.

Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program

Digital: LYNPARZA® Enrollment and Consent Form


Print: LYNPARZA® Enrollment and Consent Form

*Lynparza® is part of a global strategic oncology collaboration between Merck and AstraZeneca. AstraZeneca Canada Inc ("AstraZeneca") is managing the Lynparza® Patient Support Program ("Program") on behalf of both companies via its existing AstraZeneca Oncology Patient Support Program.

Lynparza® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. MERCK® is a registered trademark of Merck Sharp & Dohme LLC. Used under license. © 2023 AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.